No I do not mean MSB. Takedas best seller.
Two other problems for CYP.
The first , you are treating a large group that has a high responce rate so may be harder to show significants.
The second and probabley more significant is that you are going into the P2 without clinical evedence. Yes you have some P1 data but this is at a later stage. You may find that the patients havent got the most important markers that activate the cells.
Going forward..., page-1611
-
- There are more pages in this discussion • 520 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.005(2.38%) |
Mkt cap ! $38.84M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 20.5¢ | $11.17K | 53.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6162 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 13800 | 1 |
View Market Depth
| Last trade - 14.25pm 30/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |